根据Nuvama分析师的预测，Dr. Reddy's Laboratories预计将缓解约80%的专利到期预期EBITDA影响。这一估计基于公司及时采取措施应对挑战。分析师以预测的2027财年每股收益（EPS）的24倍对Dr. Reddy's股票进行估值，得出修订后的目标价。

Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddy’s, a global pharmaceutical company with ties to Louisiana, will close its Shreveport manufacturing plant and ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Join us on the Dr Reddys Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.16% to 1,350.65 Indian rupees Monday, on what proved to be an ...

Dr Reddy stock price went up today, 26 Dec 2024, by 0.07 %. The stock closed at 1351.25 per share. The stock is currently ...

Abhishek had been battling severe health complications for the past three months and was undergoing treatment at the hospital ...

Dec 23 2024 02:49 AM Dr Reddy's Labs top Nifty gainer, surges 9% in three sessions Dec 20 2024 12:38 PM ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Stocks like Tata Steel, Dr Reddy’s Laboratories, WPIL, Rail Vikas Nigam, Mahindra and Mahindra, Mankind Pharma, CESC, ...